Identification

Name
Amlodipine
Accession Number
DB00381  (APRD00520)
Type
Small Molecule
Groups
Approved
Description

Amlodipine is a long-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, amlodipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Some studies have shown that amlodipine also exerts inhibitory effects on voltage-gated N-type calcium channels. N-type calcium channels located in the central nervous system may be involved in nociceptive signaling and pain sensation. Amlodipine is used to treat hypertension and chronic stable angina.

Structure
Thumb
Synonyms
  • (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
  • 3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
  • 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
  • Amlodipine
  • Amlodipine free base
  • Amlodipino
  • Amlodipinum
Product Ingredients
IngredientUNIICASInChI Key
Amlodipine besylate864V2Q084H111470-99-6ZPBWCRDSRKPIDG-UHFFFAOYSA-N
Amlodipine maleateCQ27G2BZJM88150-47-4TZNOWAJJWCGILX-BTJKTKAUSA-N
Amlodipine mesylate291Y33EZHA246852-12-0MUVFCHUBATVFPP-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-amlodipineTablet2.5 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-amlodipineTablet5 mgOralAccel Pharma Inc2010-03-052016-10-19Canada
Accel-amlodipineTablet10 mgOralAccel Pharma Inc2010-03-052016-10-19Canada
Act AmlodipineTablet10 mgOralActavis Pharma Company2009-07-10Not applicableCanada
Act AmlodipineTablet2.5 mgOralActavis Pharma Company2010-03-02Not applicableCanada
Act AmlodipineTablet5 mgOralActavis Pharma Company2009-07-10Not applicableCanada
Ag-amlodipineTablet5 mgOralAngita Pharma Inc.2014-09-25Not applicableCanada
Ag-amlodipineTablet10 mgOralAngita Pharma Inc.2014-09-25Not applicableCanada
Ag-amlodipineTablet2.5 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
AmlodipineTablet5 mgOralMeliapharm Inc2011-04-082014-06-25Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmlodipineTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
AmlodipineTablet5 mg/1OralMacleods Pharmaceuticals Limited2012-04-13Not applicableUs
AmlodipineTablet10 mg/1OralRemedy Repack2011-04-132016-10-13Us
AmlodipineTablet10 mg/1OralMacleods Pharmaceuticals Limited2012-04-13Not applicableUs
Amlodipine BesylateTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-20Not applicableUs
Amlodipine besylateTablet10 mg/1OralWest Ward Pharmaceutical2011-04-12Not applicableUs
Amlodipine BesylateTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-11-132017-05-24Us
Amlodipine BesylateTablet10 mg/1OralUpsher Smith Laboratories2007-07-09Not applicableUs
Amlodipine besylateTablet5 mg/1OralHikma Pharmaceutical2011-04-12Not applicableUs
Amlodipine BesylateTablet5 mg/1OralPhysicians Total Care, Inc.2007-03-28Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amlodipine BesylateTablet5 mg/1OralRemedy Repack2017-11-01Not applicableUs
Amlodipine BesylateTablet10 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
Amlodipine BesylateTablet2.5 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
Amlodipine BesylateTablet5 mg/1OralRemedy Repack2017-11-10Not applicableUs
Amlodipine BesylateTablet5 mg/1OralRising Pharmaceuticals2017-11-07Not applicableUs
International/Other Brands
Aforbes (Merck) / Agen (Zentiva) / Aken (Kendrick Farmaceutica) / Amcard (Apex Pharma Ltd) / Amdepin (Cadila Pharmaceuticals) / Amdipin (Laboratorios Lafrancol) / Amlocard (AWD (Germany)) / Amlod / Amlodine (Sumitomo Pharmaceuticals) / Amlodipin / Amlodipin-Mepha 5/10 (Mepha Pharma AG) / Amlodipine 5 (PT KALBE FARMA Tbk) / Amlodis (Eczacibasi (Turkey)) / Amlong (Micro Labs) / Amlopin (Lek) / Amlopine (Berlin) / Amlostin (Discovery Pharmaceuticals) / Amlosun (Sun Pharmaceutical) / Amlovas (Macleods Pharmaceuticals Ltd) / Amlovasc (Dr. Reddy's Laboratories) / Amlozek (Adamed) / Amvaz (Reddy (Malaysia)) / Asomex (Emcure Pharmaceuticals) / Atecard-AM (Alembic Ltd) / Camlodin (Square) / Coroval (Sandoz (Argentina)) / Dailyvasc (Xeno Pharmaceuticals) / Istin / Lama (Stadmed Private Limited) / Lodip (TIME Pharmaceuticals) / Lodopin (Merck Pakistan) / Lopin (Edruc Ltd) / Nelod (The Kemiko Pharmaceuticals Ltd) / Nopidin (Ad-din Pharmaceuticals Ltd) / Nordip / Perivasc / Pharex Amlodipine (PHAREX HealthCorp) / Tenox (Krka)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AmlobenzAmlodipine besylate (10 mg/1) + Benazepril Hydrochloride (20 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0341 01 nlmimage10 c238e107
AmlobenzAmlodipine besylate (5 mg/1) + Benazepril Hydrochloride (10 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0339 01 nlmimage10 6d03b6bd
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril Hydrochloride (10 mg/1)CapsuleOralTeva2007-05-18Not applicableUs00093 7371 01 nlmimage10 ce19671b
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (10 mg/1) + Benazepril Hydrochloride (20 mg/1)CapsuleOralNucare Pharmaceuticals, Inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (10 mg/1) + Benazepril Hydrochloride (40 mg/1)CapsuleOralMylan Pharmaceuticals2012-02-20Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril Hydrochloride (10 mg/1)CapsuleOralActavis Pharma Company2010-10-13Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (10 mg/1) + Benazepril Hydrochloride (40 mg/1)CapsuleOralNucare Pharmaceuticals, Inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (2.5 mg/1) + Benazepril Hydrochloride (10 mg/1)CapsuleOralCitron Pharma LLC2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril Hydrochloride (20 mg/1)CapsuleOralNu Care Pharmaceuticals,inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (10 mg/1) + Benazepril Hydrochloride (40 mg/1)CapsuleOralTeva2011-07-20Not applicableUs00093 7671 01 nlmimage10 fe26ff27
Categories
UNII
1J444QC288
CAS number
88150-42-9
Weight
Average: 408.876
Monoisotopic: 408.145199627
Chemical Formula
C20H25ClN2O5
InChI Key
HTIQEAQVCYTUBX-UHFFFAOYSA-N
InChI
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
IUPAC Name
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC

Pharmacology

Indication

For the treatment of hypertension and chronic stable angina.

Structured Indications
Pharmacodynamics

Amlodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that DHP CCBs target L-type calcium channels, the major channel in muscle cells that mediate contraction; however, some studies have indicated that amlodipine also binds to and inhibits N-type calcium channels (see references in Targets section). Similar to other DHP CCBs, amlodipine binds directly to inactive L-type calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives amlodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, amlodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Amlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of amlodipine result in an overall decrease in blood pressure. Amlodipine is a long-acting CCB that may be used to treat mild to moderate essential hypertension and exertion-related angina (chronic stable angina). Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase I activity causing cellular pH increases which may be involved in regulating intracelluar calcium influx through calcium channels.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-3
inhibitor
Human
UVoltage-gated calcium channel beta 1 subunit splice variant CavB1d
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
USphingomyelin phosphodiesteraseNot AvailableHuman
Absorption

Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 6-12 hour following oral administration. Its estimated bioavailability is 64-90%. Absorption is not affected by food.

Volume of distribution
Not Available
Protein binding

97.5%

Metabolism

Hepatic. Metabolized extensively (90%) to inactive metabolites via the cytochrome P450 3A4 isozyme.

Route of elimination

Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.

Half life

30-50 hours

Clearance
Not Available
Toxicity

Gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to an including shock with fatal outcome have been reported.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Amlodipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Natriuretic peptides A---(A;A)AA alleleEffect Directly StudiedPatients with this genotype have increased risk of adverse cardiovascular outcomes with diuretics.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Amlodipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Amlodipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Amlodipine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Acebutolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Amlodipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Amlodipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Amlodipine is combined with Aliskiren.Approved, Investigational
AlprenololAmlodipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanAmlodipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineAmlodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Amlodipine can be decreased when combined with Amiodarone.Approved, Investigational
AmobarbitalAmobarbital may increase the hypotensive activities of Amlodipine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Amlodipine.Approved, Investigational
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Amlodipine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Amlodipine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Amlodipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amlodipine is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Amlodipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Amlodipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Amlodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Amlodipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Amlodipine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Amlodipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Amlodipine.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amlodipine resulting in a loss in efficacy.Approved, Investigational
AtazanavirThe metabolism of Amlodipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Amlodipine.Approved
AtomoxetineThe metabolism of Amlodipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Atosiban.Approved, Investigational
Atracurium besylateAmlodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Amlodipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Amlodipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Amlodipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Amlodipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Amlodipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Amlodipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Amlodipine.Approved
BepridilAmlodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amlodipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Amlodipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Amlodipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Amlodipine.Approved, Investigational
BimatoprostAmlodipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Amlodipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Amlodipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Amlodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amlodipine.Approved
BQ-123Amlodipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Amlodipine.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amlodipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Amlodipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Amlodipine.Experimental
BucindololBucindolol may increase the hypotensive activities of Amlodipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Amlodipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amlodipine.Approved, Investigational
BupranololAmlodipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Amlodipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Amlodipine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amlodipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Amlodipine.Experimental
CafedrineAmlodipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Canagliflozin.Approved
CandesartanAmlodipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Candesartan cilexetil.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Amlodipine.Withdrawn
CandoxatrilAmlodipine may increase the hypotensive activities of Candoxatril.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Amlodipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Captopril.Approved
CarbamazepineThe metabolism of Amlodipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Amlodipine.Approved
CarbomycinThe metabolism of Amlodipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Amlodipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Amlodipine.Approved
CeliprololAmlodipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Amlodipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Amlodipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Amlodipine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Amlodipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amlodipine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amlodipine.Approved
CicletanineAmlodipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Amlodipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Amlodipine.Approved, Investigational
CimetidineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Amlodipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Amlodipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Amlodipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amlodipine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine.Approved, Nutraceutical
CloranololAmlodipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Amlodipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amlodipine.Approved
CobicistatThe metabolism of Amlodipine can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amlodipine.Approved
ConivaptanThe serum concentration of Amlodipine can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Amlodipine.Investigational
CrizotinibThe metabolism of Amlodipine can be decreased when combined with Crizotinib.Approved
CryptenamineAmlodipine may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideAmlodipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideAmlodipine may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amlodipine.Approved
DabrafenibThe serum concentration of Amlodipine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Amlodipine.Investigational
DarunavirThe metabolism of Amlodipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Amlodipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Amlodipine.Approved, Investigational
DeferasiroxThe serum concentration of Amlodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilAmlodipine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Amlodipine can be decreased when combined with Delavirdine.Approved
DeserpidineAmlodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amlodipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Amlodipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Amlodipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Diclofenamide.Approved
diethylnorspermineAmlodipine may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Amlodipine.Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Amlodipine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Amlodipine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Amlodipine.Experimental
DihydroergotamineThe metabolism of Amlodipine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Amlodipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dipyridamole.Approved
DorzolamideAmlodipine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amlodipine.Approved, Investigational
DoxycyclineThe metabolism of Amlodipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Amlodipine can be decreased when combined with Dronedarone.Approved
DuloxetineAmlodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Amlodipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amlodipine.Approved
EfavirenzThe serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Amlodipine.Approved
EfonidipineAmlodipine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Enalapril.Approved, Vet Approved
EnalaprilatAmlodipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Amlodipine.Experimental
EnzalutamideThe serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide.Approved
EpanololAmlodipine may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eplerenone.Approved
EpoprostenolAmlodipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amlodipine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amlodipine.Approved
ErythromycinThe metabolism of Amlodipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Amlodipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amlodipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Felodipine.Approved, Investigational
FenoldopamAmlodipine may increase the hypotensive activities of Fenoldopam.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Amlodipine.Experimental
Ferulic acidAmlodipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Amlodipine.Approved, Investigational
FluconazoleThe serum concentration of Amlodipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Amlodipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Amlodipine.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Amlodipine.Approved
FluvoxamineThe metabolism of Amlodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Amlodipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amlodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Amlodipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Amlodipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amlodipine can be increased when it is combined with Fusidic Acid.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Amlodipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Amlodipine.Approved, Vet Approved
GuanabenzAmlodipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Amlodipine.Approved
GuanazodineAmlodipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineAmlodipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Guanfacine.Approved, Investigational
GuanoclorAmlodipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAmlodipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAmlodipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Amlodipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Amlodipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amlodipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Amlodipine.Experimental
HexamethoniumAmlodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Amlodipine.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Amlodipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Amlodipine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAmlodipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IdelalisibThe serum concentration of Amlodipine can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Amlodipine.Approved, Investigational
ImatinibThe metabolism of Amlodipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Amlodipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amlodipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Indapamide.Approved
IndenololAmlodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Amlodipine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Amlodipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Amlodipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Amlodipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Amlodipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Amlodipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Amlodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amlodipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Amlodipine.Approved
ItraconazoleThe metabolism of Amlodipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Amlodipine can be increased when it is combined with Ivacaftor.Approved
JosamycinThe metabolism of Amlodipine can be decreased when combined with Josamycin.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Amlodipine.Investigational
KetoconazoleThe metabolism of Amlodipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Amlodipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Labetalol.Approved
LacidipineAmlodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostAmlodipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amlodipine.Approved
LercanidipineAmlodipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amlodipine.Approved, Investigational
LevodopaAmlodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Amlodipine.Approved, Investigational
LinsidomineAmlodipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Amlodipine.Approved, Investigational
LofexidineAmlodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Amlodipine can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Losartan.Approved
LovastatinThe metabolism of Amlodipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Amlodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Amlodipine can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Amlodipine.Illicit, Investigational, Withdrawn
MacitentanAmlodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineAmlodipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Amlodipine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mecamylamine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Amlodipine.Approved, Nutraceutical, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Amlodipine.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Amlodipine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amlodipine.Approved
MethoserpidineAmlodipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Amlodipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Amlodipine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Amlodipine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Amlodipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amlodipine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Amlodipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amlodipine.Approved, Investigational
MetyrosineAmlodipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Amlodipine.Experimental
MibefradilAmlodipine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Amlodipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Amlodipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Amlodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Amlodipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Amlodipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amlodipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Amlodipine.Investigational
MitotaneThe serum concentration of Amlodipine can be decreased when it is combined with Mitotane.Approved
MivacuriumAmlodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Amlodipine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Amlodipine.Approved, Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Amlodipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amlodipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Amlodipine.Approved, Investigational
MuzolimineAmlodipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Amlodipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Amlodipine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nadolol.Approved
NafcillinThe metabolism of Amlodipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Amlodipine.Approved
NaftopidilAmlodipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amlodipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Amlodipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Amlodipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Amlodipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Amlodipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Amlodipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Amlodipine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Amlodipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Amlodipine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Amlodipine.Experimental
NiguldipineAmlodipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Amlodipine.Investigational
NilotinibThe metabolism of Amlodipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineAmlodipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amlodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nisoldipine.Approved
NitrendipineAmlodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Amlodipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideAmlodipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Amlodipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Amlodipine.Approved, Vet Approved
ObinutuzumabAmlodipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Amlodipine.Withdrawn
OlaparibThe metabolism of Amlodipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Amlodipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amlodipine.Approved, Investigational
OmapatrilatAmlodipine may increase the hypotensive activities of Omapatrilat.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Amlodipine.Experimental
OsimertinibThe serum concentration of Amlodipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Amlodipine.Approved
OxprenololAmlodipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amlodipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Amlodipine.Investigational
PalbociclibThe serum concentration of Amlodipine can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Amlodipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amlodipine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Amlodipine.Approved
PentobarbitalThe metabolism of Amlodipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumAmlodipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Amlodipine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Amlodipine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Amlodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Amlodipine.Withdrawn
PhenobarbitalThe metabolism of Amlodipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineAmlodipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Amlodipine.Withdrawn
PhentolamineAmlodipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amlodipine.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Amlodipine.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amlodipine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Amlodipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Amlodipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Amlodipine.Withdrawn
Platelet Activating FactorAmlodipine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideAmlodipine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Amlodipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Amlodipine.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Amlodipine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Prazosin.Approved
PrimidoneThe metabolism of Amlodipine can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Amlodipine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amlodipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amlodipine.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Amlodipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Amlodipine.Approved
QuinineQuinine may increase the hypotensive activities of Amlodipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Amlodipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Amlodipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amlodipine.Approved, Investigational
RapacuroniumAmlodipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Amlodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amlodipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Amlodipine.Approved
RescinnamineAmlodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amlodipine.Approved, Investigational
RifabutinThe metabolism of Amlodipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Amlodipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Amlodipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amlodipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Amlodipine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Amlodipine is combined with Riociguat.Approved
RisperidoneAmlodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabAmlodipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amlodipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amlodipine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Amlodipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Amlodipine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Amlodipine.Approved
SafrazineSafrazine may increase the hypotensive activities of Amlodipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Amlodipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amlodipine.Approved, Vet Approved
SaprisartanAmlodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Amlodipine can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Amlodipine.Approved, Investigational, Vet Approved
SelexipagAmlodipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Amlodipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amlodipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amlodipine.Approved
SiltuximabThe serum concentration of Amlodipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Amlodipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amlodipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Amlodipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Amlodipine.Approved, Investigational
SitaxentanAmlodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Amlodipine.Approved
SolithromycinThe metabolism of Amlodipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sotalol.Approved
SpiraprilAmlodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Amlodipine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Amlodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amlodipine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Amlodipine.Approved
SulfisoxazoleThe metabolism of Amlodipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Amlodipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
TalinololAmlodipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Amlodipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Amlodipine.Approved
TelaprevirThe metabolism of Amlodipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Amlodipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Amlodipine is combined with Telmisartan.Approved, Investigational
TemocaprilAmlodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Amlodipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Amlodipine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Amlodipine.Experimental
TerlipressinAmlodipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineAmlodipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amlodipine.Approved, Investigational, Withdrawn
TheodrenalineAmlodipine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amlodipine.Approved, Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Amlodipine.Approved
TiboloneAmlodipine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Amlodipine can be decreased when combined with Ticlopidine.Approved
TicrynafenAmlodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Amlodipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Amlodipine.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Amlodipine.Approved
TocilizumabThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineAmlodipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amlodipine.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Amlodipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Amlodipine.Approved, Vet Approved
TolonidineAmlodipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Amlodipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amlodipine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amlodipine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Amlodipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Amlodipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Amlodipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Amlodipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Amlodipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene.Approved
TrichlormethiazideAmlodipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Amlodipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Amlodipine.Approved, Investigational
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Amlodipine.Approved, Investigational
TylosinThe metabolism of Amlodipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Amlodipine.Approved, Experimental
UdenafilUdenafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
UnoprostoneAmlodipine may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Amlodipine.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Amlodipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Amlodipine.Approved
VenlafaxineThe metabolism of Amlodipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Verapamil.Approved
VincamineAmlodipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amlodipine.Approved, Investigational
VinpocetineAmlodipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Amlodipine can be decreased when combined with Voriconazole.Approved, Investigational
XipamideAmlodipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineAmlodipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Amlodipine.Approved, Vet Approved
ZiprasidoneThe metabolism of Amlodipine can be decreased when combined with Ziprasidone.Approved
ZofenoprilAmlodipine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
  • Avoid natural licorice.
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of amlodipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of amlodipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

References

Synthesis Reference
US4572909
General References
  1. Nayler WG, Gu XH: The unique binding properties of amlodipine: a long-acting calcium antagonist. J Hum Hypertens. 1991 Aug;5 Suppl 1:55-9. [PubMed:1834847]
  2. van Zwieten PA: Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clin Cardiol. 1994 Sep;17(9 Suppl 3):III3-6. [PubMed:9156957]
External Links
Human Metabolome Database
HMDB05018
KEGG Compound
C06825
PubChem Compound
2162
PubChem Substance
46507214
ChemSpider
2077
ChEBI
2668
ChEMBL
CHEMBL1491
Therapeutic Targets Database
DAP000139
PharmGKB
PA448388
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Amlodipine
ATC Codes
C09DB05 — Irbesartan and amlodipineC09DB01 — Valsartan and amlodipineC09DB04 — Telmisartan and amlodipineC09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazideC09DX01 — Valsartan, amlodipine and hydrochlorothiazideC09DB07 — Candesartan and amlodipineC09DB02 — Olmesartan medoxomil and amlodipineC10BX03 — Atorvastatin and amlodipineC08GA02 — Amlodipine and diureticsC10BX11 — Atorvastatin, amlodipine and perindoprilC09DB06 — Losartan and amlodipineC09BB03 — Lisinopril and amlodipineC08CA01 — AmlodipineC09BB07 — Ramipril and amlodipineC09XA54 — Aliskiren, amlodipine and hydrochlorothiazideC09XA53 — Aliskiren and amlodipineC10BX09 — Rosuvastatin and amlodipineC09BX01 — Perindopril, amlodipine and indapamideC10BX07 — Rosuvastatin, amlodipine and lisinoprilC09BB04 — Perindopril and amlodipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (91.4 KB)
MSDS
Download (74.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealhty1
1CompletedNot AvailableHealthy Volunteers14
1CompletedNot AvailableHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailableHypertensive3
1CompletedBasic ScienceHypertension(HTN)1
1CompletedBasic ScienceHypertensive1
1CompletedDiagnosticHypertensive1
1CompletedOtherHypertensive1
1CompletedPreventionHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedSupportive CareHealthy Male Volunteers1
1CompletedTreatmentBioequivalence1
1CompletedTreatmentCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) Infections / Hypertensive1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentFasting2
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Male Volunteers1
1CompletedTreatmentHealthy Volunteers19
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHyperlipidemias / Hypertensive3
1CompletedTreatmentHypertension and Dyslipidemia1
1CompletedTreatmentHypertensive9
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1
1Not Yet RecruitingTreatmentHealthy Volunteers1
1Not Yet RecruitingTreatmentHypertensive1
1RecruitingTreatmentHyperlipidemias / Hypertensive1
1TerminatedTreatmentHyperlipidemias / Hypertensive1
1Unknown StatusBasic ScienceHealthy Volunteers1
1WithdrawnTreatmentChronic Hepatitis C Infection / Hypertensive1
1, 2CompletedTreatmentPancreatitis1
1, 2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
2Active Not RecruitingPreventionHyperlipidemias / Hypertensive1
2CompletedNot AvailableConcurrent Obesity / Hypertensive1
2CompletedTreatmentAbdominal Aortic Aneurysms (AAA)1
2CompletedTreatmentAngina, Prinzmetal's1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
2CompletedTreatmentEndothelial Dysfunction / High Blood Pressure / Insulin Resistance / Metabolic Syndromes1
2CompletedTreatmentHypertension,Essential3
2CompletedTreatmentHypertensive6
2RecruitingTreatmentHigh Blood Pressure / Hypertensive1
2RecruitingTreatmentHypertension,Essential1
2SuspendedTreatmentChronic Heart Failure (CHF)1
2TerminatedTreatmentAnkle Edema / Hypertensive1
2TerminatedTreatmentHypertensive / Obesity, Abdominal1
2Unknown StatusTreatmentHypertension,Essential1
2, 3CompletedPreventionThalassaemic disorders1
2, 3CompletedTreatmentCardiac Failure / Congestive Heart Failure (CHF) / Heart Failure, Unspecified1
2, 3CompletedTreatmentGrade I or II Essential Hypertension1
2, 3CompletedTreatmentHypertension,Essential1
2, 3CompletedTreatmentThalassemia Major (TM)1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / Hypertensive / Subjective Cognitive Decline1
2, 3RecruitingTreatmentHypertensive / Sleep Apnea Syndrome1
2, 3Unknown StatusTreatmentHypertension,Essential2
3Active Not RecruitingTreatmentDyslipidemias / Hypertensive1
3CompletedDiagnosticHypertensive1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / Hypercholesterolaemia / Hypertensive / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedTreatmentChronic Kidney Disease (CKD) / Hypertensive1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentHypertension,Essential12
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentHypertensive59
3CompletedTreatmentHypertensive / Metabolic Syndromes1
3CompletedTreatmentHypertensive / Obstructive Sleep Apnea (OSA)1
3CompletedTreatmentHypertensive / Transplantation, Kidney1
3CompletedTreatmentModerate to Severe Hypertension1
3CompletedTreatmentProteinuria1
3CompletedTreatmentAcute iron intoxication / Thalassaemic disorders1
3Not Yet RecruitingTreatmentCerebral Small Vessels Disease1
3RecruitingTreatmentDyslipidemia With Hypertension1
3RecruitingTreatmentDyslipidemias / Hypertension,Essential1
3RecruitingTreatmentHyperlipidemias / Hypertensive2
3RecruitingTreatmentHypertensive1
3RecruitingTreatmentHypertensive / Sleep Apnea Syndrome1
3TerminatedTreatmentCardiovascular Events1
3Unknown StatusTreatmentDepression1
3Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
3Unknown StatusTreatmentHypertension,Essential1
3WithdrawnTreatmentHypertensive2
4Active Not RecruitingBasic ScienceArterial hypoxia / Obstructive Sleep Apnea (OSA) / Sleep Apnea Syndrome1
4Active Not RecruitingTreatmentChronic Hypertension in Pregnancy1
4CompletedNot AvailableHypertensive1
4CompletedHealth Services ResearchAsthma Bronchial1
4CompletedOtherCoronary Artery Disease / Type 2 Diabetes Mellitus1
4CompletedPreventionCardiovascular Disease (CVD) / Hypertensive1
4CompletedPreventionCoronary Artery Atherosclerosis / Hypertensive1
4CompletedPreventionHypertensive2
4CompletedPreventionHypertensive / Type 2 Diabetes Mellitus1
4CompletedPreventionNonvalvular Atrial Fibrillation2
4CompletedPreventionWe Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria1
4CompletedTreatmentAlbuminuria1
4CompletedTreatmentAlbuminuria / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentAngina Pectoris / Hypercholesterolaemia / Hypertensive1
4CompletedTreatmentAnginal Pain1
4CompletedTreatmentBMI >30 kg/m2 / Diabetes / Hypertensive1
4CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
4CompletedTreatmentBlood Pressures1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentDiabetes Mellitus (DM) / Hypertensive1
4CompletedTreatmentDiabetes / Hypertensive / Proteinuria2
4CompletedTreatmentDiastolic Dysfunction / Hypertensive1
4CompletedTreatmentDyslipidemias / Hypertensive3
4CompletedTreatmentEssential Hypertension ( Mild to Moderate)1
4CompletedTreatmentHigh Blood Pressure / Hypertension,Essential1
4CompletedTreatmentHigh Blood Pressure / Hypertensive1
4CompletedTreatmentHypercholesterolaemia / Hypertensive1
4CompletedTreatmentHyperlipidemias / Hypertensive1
4CompletedTreatmentHypertension,Essential5
4CompletedTreatmentHypertensive31
4CompletedTreatmentHypertensive / Left Ventricle Hypertrophy1
4CompletedTreatmentHypertensive / Left Ventricular Hypertrophy1
4CompletedTreatmentHypertensive / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Pharmacogenetics1
4CompletedTreatmentHypertensive / Strokes1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentIschaemic Heart Diseases1
4CompletedTreatmentKidney Failure,Chronic1
4CompletedTreatmentMyocardial Ischemia1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStroke, Ischemic1
4Not Yet RecruitingTreatmentArterial Hypertension2
4Not Yet RecruitingTreatmentArterial Hypertension / Blood Pressures / Dyslipidemias / Lipid Metabolism Disorders1
4Not Yet RecruitingTreatmentHypertensive1
4Not Yet RecruitingTreatmentQuality of Life1
4RecruitingDiagnosticAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Overlap Syndrome1
4RecruitingDiagnosticHypertensive / Type 2 Diabetes Mellitus1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentBlood Pressure, High1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentEfficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension1
4RecruitingTreatmentHypertensive3
4RecruitingTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4TerminatedNot AvailableHypertension and Cardiovascular Risk Factors1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedTreatmentDiabetes / Hypertensive / Stage 2 Hypertension1
4TerminatedTreatmentHypertension With Metabolic Syndrome1
4TerminatedTreatmentHypertensive1
4Unknown StatusDiagnosticCoronary Artery Disease1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentAlbuminuria / Diabetes Mellitus (DM) / Hypertensive1
4Unknown StatusTreatmentArterial and Arteriolar Disorders1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentCoronary Artery Disease2
4Unknown StatusTreatmentDialysis therapy / Hypertensive1
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentHypertensive5
4WithdrawnDiagnosticBMI >30 kg/m2 / Hypertensive1
4WithdrawnTreatmentDiabetes Mellitus (DM) / Hypertensive1
4WithdrawnTreatmentHypertensive2
Not AvailableActive Not RecruitingTreatmentBeta Thalassemia Major1
Not AvailableCompletedNot AvailableAngina Pectoris / Hypercholesterolaemia / Hypercholesterolemia, Familial / Hypertensive1
Not AvailableCompletedNot AvailableDiabetes Complications / Diabetes, Diabetes Mellitus Type 1 / Eye Diseases / Retinopathy, Diabetic1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHypertensive4
Not AvailableCompletedDiagnosticHypertensive1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Hypertensive1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Hypertensive1
Not AvailableCompletedTreatmentFemale Infertility Associated With Anovulation1
Not AvailableCompletedTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF) / Left Ventricular Hypertrophy/Hypertension / Pulmonary Diseases1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableCompletedTreatmentHypertensive2
Not AvailableCompletedTreatmentHypertensive / Lower Urinary Tract Symptoms (LUTS)1
Not AvailableCompletedTreatmentHypertensive / Plasma Renin Activity1
Not AvailableCompletedTreatmentChronic, stable Angina pectoris / Hypertensive / Vasospastic Angina2
Not AvailableCompletedTreatmentMyocardial Ischemia1
Not AvailableNot Yet RecruitingNot AvailableHypertensive1
Not AvailableRecruitingNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingNot AvailableHypertension,Essential1
Not AvailableRecruitingNot AvailableLower Leg Edema / Orthostatic Hypertension1
Not AvailableRecruitingDiagnosticArterial Hypertension1
Not AvailableRecruitingDiagnosticHypertensive1
Not AvailableRecruitingTreatmentAcute iron intoxication / Beta-Thalassemia1
Not AvailableTerminatedTreatmentAbdominal Aortic Aneurysms (AAA) / Hypertensive1
Not AvailableTerminatedTreatmentAortic Compliance / Diastolic Function / Insulin Sensitivity1
Not AvailableTerminatedTreatmentHypertensive1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusTreatmentBlood Pressure Variability / Intracranial Artery Stenosis1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusTreatmentHypertensive1

Pharmacoeconomics

Manufacturers
  • Synthon pharmaceuticals inc
  • Actavis totowa llc
  • Alkem laboratories ltd
  • Amneal pharmaceuticals ny llc
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Gedeon richter usa inc
  • Genpharm inc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Lek pharmaceuticals dd
  • Lupin ltd
  • Matrix laboratories ltd
  • Mutual pharmacal co
  • Mylan laboratories inc
  • Orchid healthcare
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Torrent pharmaceuticals ltd
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Wockhardt ltd
  • World gen llc
  • Zydus pharmaceuticals usa inc
  • Pfizer inc
  • Dr reddys laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
CapsuleOral
TabletOral10.00 mg
TabletOral5.00 mg
Kit
TabletOral10.0 mg
TabletOral5.0 mg
TabletOral10 mg
TabletOral5 mg
TabletOral2.5 mg
Tablet, film coatedOral
Tablet, multilayerOral
Prices
Unit descriptionCostUnit
Amlodipine besylate powder9.99USD g
Lotrel 10-40 mg capsule5.21USD capsule
Lotrel 10-20 mg capsule4.8USD capsule
Lotrel 5-40 mg capsule4.37USD capsule
Lotrel 5-20 mg capsule4.13USD capsule
Lotrel 5-10 mg capsule3.91USD capsule
Lotrel 2.5-10 mg capsule3.83USD capsule
Norvasc 10 mg tablet3.16USD tablet
Amlodipine besylate 10 mg tablet2.42USD tablet
Norvasc 2.5 mg tablet2.36USD tablet
Norvasc 5 mg tablet2.36USD tablet
Norvasc 10 mg Tablet2.14USD tablet
Amlodipine besylate 2.5 mg tablet1.76USD tablet
Amlodipine besylate 5 mg tablet1.76USD tablet
Norvasc 5 mg Tablet1.44USD tablet
Amlodipine 10 mg Tablet1.03USD tablet
Apo-Amlodipine 10 mg Tablet1.03USD tablet
Co Amlodipine 10 mg Tablet1.03USD tablet
Gd-Amlodipine 10 mg Tablet1.03USD tablet
Jamp-Amlodipine 10 mg Tablet1.03USD tablet
Mylan-Amlodipine 10 mg Tablet1.03USD tablet
Novo-Amlodipine 10 mg Tablet1.03USD tablet
Phl-Amlodipine 10 mg Tablet1.03USD tablet
Pms-Amlodipine 10 mg Tablet1.03USD tablet
Ran-Amlodipine 10 mg Tablet1.03USD tablet
Ratio-Amlodipine 10 mg Tablet1.03USD tablet
Sandoz Amlodipine 10 mg Tablet1.03USD tablet
Amlodipine 5 mg Tablet0.7USD tablet
Apo-Amlodipine 5 mg Tablet0.7USD tablet
Co Amlodipine 5 mg Tablet0.7USD tablet
Gd-Amlodipine 5 mg Tablet0.7USD tablet
Jamp-Amlodipine 5 mg Tablet0.7USD tablet
Mylan-Amlodipine 5 mg Tablet0.7USD tablet
Novo-Amlodipine 5 mg Tablet0.7USD tablet
Phl-Amlodipine 5 mg Tablet0.7USD tablet
Pms-Amlodipine 5 mg Tablet0.7USD tablet
Ran-Amlodipine 5 mg Tablet0.7USD tablet
Ratio-Amlodipine 5 mg Tablet0.7USD tablet
Sandoz Amlodipine 5 mg Tablet0.7USD tablet
Phl-Amlodipine 2.5 mg Tablet0.35USD tablet
Pms-Amlodipine 2.5 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2170278No1999-08-032014-08-10Canada
US6162802No1997-12-192017-12-19Us
US5969156Yes1997-01-082017-01-08Us
US6294197Yes1997-12-182017-12-18Us
US5559111Yes1999-01-212019-01-21Us
US6395728No1999-07-082019-07-08Us
US6828339No2002-11-202022-11-20Us
US5616599Yes1996-10-252016-10-25Us
US6455574No1998-08-112018-08-11Us
US8101599No2003-05-162023-05-16Us
US8475839Yes2003-11-162023-11-16Us
US8613949No2009-12-212029-12-21Us
US8618174No2001-11-152021-11-15Us
US8183295No2003-05-162023-05-16Us
US7846961No2009-10-052029-10-05Us
US6696481No2003-04-152023-04-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178-179 °CNot Available
water solubility75.3 mg/LNot Available
logP3.00AUSTIN,RP ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0074 mg/mLALOGPS
logP2.22ALOGPS
logP1.64ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108.64 m3·mol-1ChemAxon
Polarizability42.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9479
Blood Brain Barrier-0.7744
Caco-2 permeable-0.5468
P-glycoprotein substrateSubstrate0.9102
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.8473
Renal organic cation transporterNon-inhibitor0.803
CYP450 2C9 substrateNon-substrate0.8627
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6967
CYP450 1A2 substrateInhibitor0.538
CYP450 2C9 inhibitorInhibitor0.514
CYP450 2D6 inhibitorNon-inhibitor0.7626
CYP450 2C19 inhibitorInhibitor0.5871
CYP450 3A4 inhibitorInhibitor0.8608
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6642
Ames testNon AMES toxic0.7605
CarcinogenicityNon-carcinogens0.8568
BiodegradationNot ready biodegradable0.9791
Rat acute toxicity2.5396 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8302
hERG inhibition (predictor II)Inhibitor0.8411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4u-0192000000-988fbef9dd83defbfbe0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002o-1392000000-3e9bc5dcf61b0f4cae6a
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Chlorobenzenes / Aryl chlorides / Dicarboxylic acids and derivatives / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Azacyclic compounds / Dialkyl ethers / Dialkylamines
show 7 more
Substituents
Dihydropyridinecarboxylic acid derivative / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide / Alpha,beta-unsaturated carboxylic ester
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, primary amino compound, methyl ester, monochlorobenzenes, dihydropyridine (CHEBI:2668)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated ion channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D3
Uniprot ID
Q8IZS8
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-3
Molecular Weight
123010.22 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
High voltage-gated calcium channel activity
Specific Function
Not Available
Gene Name
CACNB1
Uniprot ID
Q6TME4
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
23836.425 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Puscas I, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A: Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition. Clin Pharmacol Ther. 2000 Oct;68(4):443-9. [PubMed:11061585]
  2. Puscas L, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A: Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I. Cardiovasc Drugs Ther. 2000 Oct;14(5):523-8. [PubMed:11101200]
  3. Puscas I, Coltau M, Baican M, Pasca R, Domuta G, Hecht A: Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action. Drugs Exp Clin Res. 2001;27(2):53-60. [PubMed:11392054]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sphingomyelin phosphodiesterase activity
Specific Function
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic ac...
Gene Name
SMPD1
Uniprot ID
P17405
Uniprot Name
Sphingomyelin phosphodiesterase
Molecular Weight
69751.3 Da
References
  1. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Muhle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P: Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852. doi: 10.1371/journal.pone.0023852. Epub 2011 Aug 31. [PubMed:21909365]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97. [PubMed:11145223]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34